Astrazeneca Phar

64
Hold
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE203A01020
  • NSEID: ASTRAZEN
  • BSEID: 506820
INR
9,186.50
-2.4 (-0.03%)
BSENSE

Dec 05

BSE+NSE Vol: 1.18 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024

Compare Profit and Loss Results of Astrazeneca Phar
Markets Mojo
Figures in Cr
standalone - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,716.00
2,281.00
-565.00
-24.77%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,716.00
2,281.00
-565.00
-24.77%
Expenditure (Ex Depriciation)
Stock Adjustments
-332.00
25.00
-357.00
-1,428.00%
Raw Materials Consumed
1,295.00
785.00
510.00
64.97%
Power & Fuel Cost
5.00
3.00
2.00
66.67%
Employee Cost
257.00
371.00
-114.00
-30.73%
Operating Expenses
18.00
50.00
-32.00
-64.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
93.00
117.00
-24.00
-20.51%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
13.00
45.00
-32.00
-71.11%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
1,462.00
1,541.00
-79.00
-5.13%
Operating Profit (PBDIT) excl Other Income
253.00
740.00
-487.00
-65.81%
Other Income
40.00
172.00
-132.00
-76.74%
Operating Profit (PBDIT)
294.00
912.00
-618.00
-67.76%
Interest
1.00
8.00
-7.00
-87.50%
Profit before Depriciation and Tax
293.00
904.00
-611.00
-67.59%
Depreciation
39.00
60.00
-21.00
-35.00%
Profit Before Taxation & Exceptional Items
253.00
843.00
-590.00
-69.99%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
156.00
1,016.00
-860.00
-84.65%
Provision for Tax
40.00
248.00
-208.00
-83.87%
Profit After Tax
115.00
767.00
-652.00
-85.01%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
578.00
1,828.00
-1,250.00
-68.38%
Profit Available for appropriations
693.00
2,595.00
-1,902.00
-73.29%
Appropriations
693.00
2,595.00
-1,902.00
-73.29%
Equity Dividend (%)
1600%
1650%
-50.00
Earnings Per Share
46.3
136.46
-90.16
-66.07%
Profit And Loss - Net Sales
Net Sales 1,716.29 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 253.97 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024

Profit And Loss - Interest
Interest 1.46 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 115.74 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024